ERBB2 and biliary tract cancer: Additionally, Tsurutani et al. demonstrated confirmed objective responses in HER2-expressing (IHC ≥1+) non-small cell lung cancer, salivary gland cancer, endometrial cancer, and biliary tract cancer following trastuzumab-DXd treatment.